Published in Nat Chem Biol on December 01, 2006
Kinetoplastids: related protozoan pathogens, different diseases. J Clin Invest (2008) 3.59
Ascaris suum draft genome. Nature (2011) 2.16
Target assessment for antiparasitic drug discovery. Trends Parasitol (2007) 1.96
Lessons learnt from assembling screening libraries for drug discovery for neglected diseases. ChemMedChem (2008) 1.94
Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening. PLoS Negl Trop Dis (2009) 1.74
Post-translational import of protein into the endoplasmic reticulum of a trypanosome: an in vitro system for discovery of anti-trypanosomal chemical entities. Biochem J (2009) 1.46
Evolution of structure and mechanistic divergence in di-domain methyltransferases from nematode phosphocholine biosynthesis. Structure (2013) 1.45
Two approaches to discovering and developing new drugs for Chagas disease. Mem Inst Oswaldo Cruz (2009) 1.41
A screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit. PLoS Negl Trop Dis (2011) 1.39
RNA interference of Trypanosoma brucei cathepsin B and L affects disease progression in a mouse model. PLoS Negl Trop Dis (2008) 1.35
MIRO and IRbase: IT tools for the epidemiological monitoring of insecticide resistance in mosquito disease vectors. PLoS Negl Trop Dis (2009) 1.34
Identification of a κ-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis. Biochem Pharmacol (2010) 1.33
Novel non-peptidic vinylsulfones targeting the S2 and S3 subsites of parasite cysteine proteases. Bioorg Med Chem Lett (2009) 1.33
Structure-based ligand design and the promise held for antiprotozoan drug discovery. J Biol Chem (2008) 1.22
Vinyl sulfones as antiparasitic agents and a structural basis for drug design. J Biol Chem (2009) 1.18
A comparative chemogenomics strategy to predict potential drug targets in the metazoan pathogen, Schistosoma mansoni. PLoS One (2009) 1.17
Development of protease inhibitors for protozoan infections. Curr Opin Infect Dis (2008) 1.16
A parasite cysteine protease is key to host protein degradation and iron acquisition. J Biol Chem (2008) 1.06
Target validation: linking target and chemical properties to desired product profile. Curr Top Med Chem (2011) 1.04
The global cysteine peptidase landscape in parasites. Trends Parasitol (2009) 1.02
Nonpeptidic tetrafluorophenoxymethyl ketone cruzain inhibitors as promising new leads for Chagas disease chemotherapy. J Med Chem (2010) 1.00
Repositioning of an existing drug for the neglected tropical disease Onchocerciasis. Proc Natl Acad Sci U S A (2010) 1.00
Structural and evolutionary divergence of eukaryotic protein kinases in Apicomplexa. BMC Evol Biol (2011) 0.98
Discovery and structure-activity relationships of pyrrolone antimalarials. J Med Chem (2013) 0.95
Structures, targets and recent approaches in anti-leishmanial drug discovery and development. Open Med Chem J (2011) 0.95
Chemical-biological characterization of a cruzain inhibitor reveals a second target and a mammalian off-target. Beilstein J Org Chem (2013) 0.95
Mining a cathepsin inhibitor library for new antiparasitic drug leads. PLoS Negl Trop Dis (2011) 0.93
The functional expression and characterisation of a cysteine peptidase from the invasive stage of the neuropathogenic schistosome Trichobilharzia regenti. Int J Parasitol (2008) 0.92
Development of a novel virtual screening cascade protocol to identify potential trypanothione reductase inhibitors. J Med Chem (2009) 0.91
Neglected tropical diseases. BMJ (2007) 0.90
Comparative structural, kinetic and inhibitor studies of Trypanosoma brucei trypanothione reductase with T. cruzi. Mol Biochem Parasitol (2009) 0.90
New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugs. Antimicrob Agents Chemother (2014) 0.90
Thermodynamic evaluation of ligand binding in the plant-like phosphoethanolamine methyltransferases of the parasitic nematode Haemonchus contortus. J Biol Chem (2011) 0.88
Homology modeling and molecular dynamics simulation of N-myristoyltransferase from protozoan parasites: active site characterization and insights into rational inhibitor design. J Comput Aided Mol Des (2009) 0.88
From on-target to off-target activity: identification and optimisation of Trypanosoma brucei GSK3 inhibitors and their characterisation as anti-Trypanosoma brucei drug discovery lead molecules. ChemMedChem (2013) 0.87
Determination of antiprotozoal drug mechanisms by metabolomics approaches. Parasitology (2013) 0.86
Synthesis and antileishmanial evaluation of some 2,3-disubstituted-4(3H)-quinazolinone derivatives. Org Med Chem Lett (2014) 0.85
Discovery of novel benzoxaborole-based potent antitrypanosomal agents. ACS Med Chem Lett (2010) 0.85
Synthesis, biological evaluation, and molecular modeling of 3,5-substituted-N1-phenyl-N4,N4-di-n-butylsulfanilamides as antikinetoplastid antimicrotubule agents. Bioorg Med Chem (2007) 0.85
A cysteine protease inhibitor rescues mice from a lethal Cryptosporidium parvum infection. Antimicrob Agents Chemother (2013) 0.84
Aptamers: novel molecules as diagnostic markers in bacterial and viral infections? Biomed Res Int (2013) 0.83
Molecular changes in Opisthorchis viverrini (Southeast Asian liver fluke) during the transition from the juvenile to the adult stage. PLoS Negl Trop Dis (2012) 0.83
The genome of the myxosporean Thelohanellus kitauei shows adaptations to nutrient acquisition within its fish host. Genome Biol Evol (2014) 0.82
Human p38 mitogen-activated protein kinase inhibitor drugs inhibit Plasmodium falciparum replication. Exp Parasitol (2011) 0.82
Advances in Development of New Treatment for Leishmaniasis. Biomed Res Int (2015) 0.82
Structural basis for inhibition of cathepsin B drug target from the human blood fluke, Schistosoma mansoni. J Biol Chem (2011) 0.82
In vitro anti-Toxoplasma gondii activity of root extract/fractions of Eurycoma longifolia Jack. BMC Complement Altern Med (2012) 0.82
Expression profile of the Schistosoma japonicum degradome reveals differential protease expression patterns and potential anti-schistosomal intervention targets. PLoS Comput Biol (2014) 0.81
Identification of plumbagin and sanguinarine as effective chemotherapeutic agents for treatment of schistosomiasis. Int J Parasitol Drugs Drug Resist (2013) 0.81
Nematode phospholipid metabolism: an example of closing the genome-structure-function circle. Trends Parasitol (2014) 0.81
Antiprotozoal activity of 1-phenethyl-4-aminopiperidine derivatives. Antimicrob Agents Chemother (2009) 0.79
Naphthoquinone derivatives exert their antitrypanosomal activity via a multi-target mechanism. PLoS Negl Trop Dis (2013) 0.79
Antisense antimicrobial therapeutics. Curr Opin Microbiol (2016) 0.79
Phenotypic and transcriptomic analyses of Plasmodium falciparum protein kinase A catalytic subunit inhibition. Parasitol Res (2009) 0.78
Inhibition of isoleucyl-tRNA synthetase as a potential treatment for human African Trypanosomiasis. J Biol Chem (2013) 0.78
Discovery of safe and orally effective 4-aminoquinaldine analogues as apoptotic inducers with activity against experimental visceral leishmaniasis. Antimicrob Agents Chemother (2011) 0.77
Recent advances and applications of experimental technologies in marine natural product research. Mar Drugs (2015) 0.77
Optimisation of the anti-Trypanosoma brucei activity of the opioid agonist U50488. ChemMedChem (2011) 0.77
Synthesis of a sugar-based thiosemicarbazone series and structure-activity relationship versus the parasite cysteine proteases rhodesain, cruzain, and Schistosoma mansoni cathepsin B1. Antimicrob Agents Chemother (2015) 0.76
Utilizing a dynamical description of IspH to aid in the development of novel antimicrobial drugs. PLoS Comput Biol (2013) 0.76
Thiadiazine derivatives as antiprotozoal new drugs. Open Med Chem J (2011) 0.76
Discovery of 3,3'-diindolylmethanes as potent antileishmanial agents. Eur J Med Chem (2013) 0.75
Scaffold proteins LACK and TRACK as potential drug targets in kinetoplastid parasites: Development of inhibitors. Int J Parasitol Drugs Drug Resist (2016) 0.75
Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity. Eur J Med Chem (2015) 0.75
Trypanothione reductase: a target protein for a combined in vitro and in silico screening approach. PLoS Negl Trop Dis (2015) 0.75
Facile Synthesis and Preliminary Structure-Activity Analysis of New Sulfonamides Against Trypanosoma brucei. ACS Med Chem Lett (2014) 0.75
A global comparison of the human and T. brucei degradomes gives insights about possible parasite drug targets. PLoS Negl Trop Dis (2012) 0.75
Chemogenetic Characterization of Inositol Phosphate Metabolic Pathway Reveals Druggable Enzymes for Targeting Kinetoplastid Parasites. Cell Chem Biol (2016) 0.75
An 8-hydroxyquinoline-containing polymeric micelle system is effective for the treatment of murine tegumentary leishmaniasis. Parasitol Res (2016) 0.75
Synthesis and evaluation of isatins and thiosemicarbazone derivatives against cruzain, falcipain-2 and rhodesain. Bioorg Med Chem Lett (2003) 2.54
IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J Immunol (2004) 2.47
Invasion of skin by Schistosoma cercariae. Trends Parasitol (2002) 2.44
A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target. Nat Med (2012) 2.39
Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor. PLoS Med (2007) 2.15
Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-specific immunostaining. Am J Trop Med Hyg (2009) 1.87
A multienzyme network functions in intestinal protein digestion by a platyhelminth parasite. J Biol Chem (2006) 1.82
Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening. PLoS Negl Trop Dis (2009) 1.74
Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruzain. J Med Chem (2002) 1.64
Discovery of trypanocidal compounds by whole cell HTS of Trypanosoma brucei. Chem Biol Drug Des (2006) 1.61
A cathepsin B-like protease is required for host protein degradation in Trypanosoma brucei. J Biol Chem (2004) 1.57
Complementarity between a docking and a high-throughput screen in discovering new cruzain inhibitors. J Med Chem (2010) 1.54
Proteomic analysis of Schistosoma mansoni cercarial secretions. Mol Cell Proteomics (2005) 1.54
A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection. Antimicrob Agents Chemother (2007) 1.54
Synthesis and structure-activity relationships of parasiticidal thiosemicarbazone cysteine protease inhibitors against Plasmodium falciparum, Trypanosoma brucei, and Trypanosoma cruzi. J Med Chem (2004) 1.49
IL-22+ CD4+ T cells are associated with therapeutic trichuris trichiura infection in an ulcerative colitis patient. Sci Transl Med (2010) 1.42
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease. Antimicrob Agents Chemother (2010) 1.41
A multi-enzyme cascade of hemoglobin proteolysis in the intestine of blood-feeding hookworms. J Biol Chem (2004) 1.41
A screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit. PLoS Negl Trop Dis (2011) 1.39
Blood 'n' guts: an update on schistosome digestive peptidases. Trends Parasitol (2004) 1.35
RNA interference of Trypanosoma brucei cathepsin B and L affects disease progression in a mouse model. PLoS Negl Trop Dis (2008) 1.35
Functional expression and characterization of Schistosoma mansoni cathepsin B and its trans-activation by an endogenous asparaginyl endopeptidase. Mol Biochem Parasitol (2003) 1.34
Novel non-peptidic vinylsulfones targeting the S2 and S3 subsites of parasite cysteine proteases. Bioorg Med Chem Lett (2009) 1.33
RNA interference in Schistosoma mansoni schistosomula: selectivity, sensitivity and operation for larger-scale screening. PLoS Negl Trop Dis (2010) 1.32
Development of potent purine-derived nitrile inhibitors of the trypanosomal protease TbcatB. J Med Chem (2008) 1.32
Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole. PLoS Negl Trop Dis (2010) 1.30
Host pathogen protein interactions predicted by comparative modeling. Protein Sci (2007) 1.29
Trypanosoma cruzi CYP51 inhibitor derived from a Mycobacterium tuberculosis screen hit. PLoS Negl Trop Dis (2009) 1.29
Identification of a new class of nonpeptidic inhibitors of cruzain. J Am Chem Soc (2008) 1.26
Differential use of protease families for invasion by schistosome cercariae. Biochimie (2007) 1.24
Cercarial elastase is encoded by a functionally conserved gene family across multiple species of schistosomes. J Biol Chem (2002) 1.22
A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia. Antimicrob Agents Chemother (2013) 1.22
A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection. Antimicrob Agents Chemother (2010) 1.22
Gene expression patterns during adaptation of a helminth parasite to different environmental niches. Genome Biol (2007) 1.20
Structural and functional relationships in the virulence-associated cathepsin L proteases of the parasitic liver fluke, Fasciola hepatica. J Biol Chem (2007) 1.19
Vinyl sulfones as antiparasitic agents and a structural basis for drug design. J Biol Chem (2009) 1.18
A comparative chemogenomics strategy to predict potential drug targets in the metazoan pathogen, Schistosoma mansoni. PLoS One (2009) 1.17
Proteomic analysis of skin invasion by blood fluke larvae. PLoS Negl Trop Dis (2008) 1.16
Global identification of peptidase specificity by multiplex substrate profiling. Nat Methods (2012) 1.14
The Plasmodium falciparum cysteine protease falcipain-2 captures its substrate, hemoglobin, via a unique motif. Proc Natl Acad Sci U S A (2005) 1.14
Delineation of diverse macrophage activation programs in response to intracellular parasites and cytokines. PLoS Negl Trop Dis (2010) 1.14
Upregulation of retinal dehydrogenase 2 in alternatively activated macrophages during retinoid-dependent type-2 immunity to helminth infection in mice. PLoS Pathog (2012) 1.13
Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51. PLoS Negl Trop Dis (2012) 1.12
Discovery of potent thiosemicarbazone inhibitors of rhodesain and cruzain. Bioorg Med Chem Lett (2005) 1.11
Cysteine proteinases from distinct cellular compartments are recruited to phagocytic vesicles by Entamoeba histolytica. Mol Biochem Parasitol (2002) 1.09
Aziridine-2,3-dicarboxylate inhibitors targeting the major cysteine protease of Trypanosoma brucei as lead trypanocidal agents. Bioorg Med Chem Lett (2006) 1.07
A gene family of cathepsin L-like proteases of filarial nematodes are associated with larval molting and cuticle and eggshell remodeling. Mol Biochem Parasitol (2004) 1.06
A parasite cysteine protease is key to host protein degradation and iron acquisition. J Biol Chem (2008) 1.06
Identification and optimization of inhibitors of Trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB. J Med Chem (2010) 1.04
The structure of chagasin in complex with a cysteine protease clarifies the binding mode and evolution of an inhibitor family. Structure (2007) 1.03
Structural basis for unique mechanisms of folding and hemoglobin binding by a malarial protease. Proc Natl Acad Sci U S A (2006) 1.02
Discovery of trypanocidal thiosemicarbazone inhibitors of rhodesain and TbcatB. Bioorg Med Chem Lett (2008) 1.02
High-throughput analysis of an RNAi library identifies novel kinase targets in Trypanosoma brucei. Chem Biol Drug Des (2011) 1.01
IrAE: an asparaginyl endopeptidase (legumain) in the gut of the hard tick Ixodes ricinus. Int J Parasitol (2007) 1.01
Nonpeptidic tetrafluorophenoxymethyl ketone cruzain inhibitors as promising new leads for Chagas disease chemotherapy. J Med Chem (2010) 1.00
SmCB2, a novel tegumental cathepsin B from adult Schistosoma mansoni. Mol Biochem Parasitol (2002) 1.00
Potency and selectivity of P2/P3-modified inhibitors of cysteine proteases from trypanosomes. Bioorg Med Chem Lett (2007) 1.00
Aza-peptide Michael acceptors: a new class of inhibitors specific for caspases and other clan CD cysteine proteases. J Med Chem (2004) 0.99
Metal compounds for the treatment of parasitic diseases. J Inorg Biochem (2008) 0.98
Hypothemycin, a fungal natural product, identifies therapeutic targets in Trypanosoma brucei [corrected]. Elife (2013) 0.98
Cruzain : the path from target validation to the clinic. Adv Exp Med Biol (2011) 0.98
Involvement of TNF in limiting liver pathology and promoting parasite survival during schistosome infection. Int J Parasitol (2004) 0.98
Biolistic transformation of Schistosoma mansoni with 5' flanking regions of two peptidase genes promotes tissue-specific expression. Int J Parasitol (2005) 0.98
Natural product libraries to accelerate the high-throughput discovery of therapeutic leads. J Nat Prod (2011) 0.97
A phagocytosis mutant of Entamoeba histolytica is less virulent due to deficient proteinase expression and release. Exp Parasitol (2006) 0.97
The Trypanosoma cruzi protease cruzain mediates immune evasion. PLoS Pathog (2011) 0.96
Divergent modes of enzyme inhibition in a homologous structure-activity series. J Med Chem (2009) 0.96
Identification of the major cysteine protease of Giardia and its role in encystation. J Biol Chem (2008) 0.95
The marine sponge Diacarnus bismarckensis as a source of peroxiterpene inhibitors of Trypanosoma brucei, the causative agent of sleeping sickness. J Nat Prod (2009) 0.95
A contiguous compartment functions as endoplasmic reticulum and endosome/lysosome in Giardia lamblia. Eukaryot Cell (2009) 0.94
Mining a cathepsin inhibitor library for new antiparasitic drug leads. PLoS Negl Trop Dis (2011) 0.93
In vitro and in vivo studies of the trypanocidal properties of WRR-483 against Trypanosoma cruzi. PLoS Negl Trop Dis (2010) 0.93
Aza-peptidyl Michael acceptors. A new class of potent and selective inhibitors of asparaginyl endopeptidases (legumains) from evolutionarily diverse pathogens. J Med Chem (2008) 0.93
Multiple cathepsin B isoforms in schistosomula of Trichobilharzia regenti: identification, characterisation and putative role in migration and nutrition. Int J Parasitol (2005) 0.93
Substrate specificity of schistosome versus human legumain determined by P1-P3 peptide libraries. Mol Biochem Parasitol (2002) 0.92
Developmental plasticity in schistosomes and other helminths. Int J Parasitol (2003) 0.92
Improved trypanocidal activities of cathepsin L inhibitors. Int J Antimicrob Agents (2003) 0.92
Additional insights on the bastadins: isolation of analogues from the sponge Ianthella cf. reticulata and exploration of the oxime configurations. J Nat Prod (2010) 0.90
SmCL3, a gastrodermal cysteine protease of the human blood fluke Schistosoma mansoni. PLoS Negl Trop Dis (2009) 0.89
Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents. J Med Chem (2013) 0.89
Proteomic analysis of adult S. mansoni gut contents. Mol Biochem Parasitol (2007) 0.89
The oligopeptidase B of Leishmania regulates parasite enolase and immune evasion. J Biol Chem (2010) 0.89
Antitrypanosomal activity of 5'-deoxy-5'-(iodomethylene)adenosine and related 6-N-cyclopropyladenosine analogues. J Med Chem (2006) 0.89
The common gamma chain cytokines interleukin (IL)-2 and IL-7 indirectly modulate blood fluke development via effects on CD4+ T cells. J Infect Dis (2006) 0.89
4-Aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potency. J Med Chem (2014) 0.88
Proteases from Schistosoma mansoni cercariae cleave IgE at solvent exposed interdomain regions. Mol Immunol (2007) 0.87
In vivo imaging of tissue eosinophilia and eosinopoietic responses to schistosome worms and eggs. Int J Parasitol (2005) 0.87
CoMFA and HQSAR of acylhydrazide cruzain inhibitors. Bioorg Med Chem Lett (2002) 0.87
Bis-acridines as lead antiparasitic agents: structure-activity analysis of a discrete compound library in vitro. Antimicrob Agents Chemother (2007) 0.86
Characterization of gut-associated cathepsin D hemoglobinase from tick Ixodes ricinus (IrCD1). J Biol Chem (2012) 0.86
Aza-peptide epoxides: potent and selective inhibitors of Schistosoma mansoni and pig kidney legumains (asparaginyl endopeptidases). Biol Chem (2003) 0.86
Synthesis of macrocyclic trypanosomal cysteine protease inhibitors. Bioorg Med Chem Lett (2008) 0.85
Non-peptidic cruzain inhibitors with trypanocidal activity discovered by virtual screening and in vitro assay. PLoS Negl Trop Dis (2013) 0.85
Squamous cell carcinoma antigen 1 is an inhibitor of parasite-derived cysteine proteases. FEBS Lett (2007) 0.84
Structure-guided development of selective TbcatB inhibitors. J Med Chem (2009) 0.84
Schistosome serine protease inhibitors: parasite defense or homeostasis? An Acad Bras Cienc (2011) 0.84
Investigation of the proteolytic functions of an expanded cercarial elastase gene family in Schistosoma mansoni. PLoS Negl Trop Dis (2012) 0.84
Aza-peptidyl Michael acceptor and epoxide inhibitors--potent and selective inhibitors of Schistosoma mansoni and Ixodes ricinus legumains (asparaginyl endopeptidases). J Med Chem (2009) 0.84
An image-based assay for high throughput screening of Giardia lamblia. J Microbiol Methods (2011) 0.84
A surface amebic cysteine proteinase inactivates interleukin-18. Infect Immun (2003) 0.84